Company profile

H. Lundbeck

CNS-focused pharma

Public Market Listing

HLUN.BNasdaq Copenhagen

Nasdaq Copenhagen primary exchange listing

Live quotes, historical charts, and market capitalization for H. Lundbeck are available on Yahoo Finance.

External market data link · No third-party exchange redistribution

Assets

(9 total)

9Total Assets

6Approved

2Phase 3 / Filed

1Phase 1–2 / Early

5Diseases

Showing 9 of 9 assets

		Target & Modality
Aripiprazole (Abilify Maintena)(Abilify Maintena)	Approved	Dopamine D2 and serotonin 5-HT1A receptors (partial agonist) · Dopamine D2/D3 and serotonin 5-HT1A receptor · Dopamine D2 receptor (partial agonist)Small molecule	Schizophrenia
Aripiprazole (Abilify)(Abilify)	Approved	Dopamine D2/D3 and serotonin 5-HT1A receptorSmall molecule	Schizophrenia
Brexpiprazole (Rexulti)(Rexulti)	Approved	Dopamine D2/D3 and serotonin 5-HT1A receptorSmall molecule	Alzheimer's DiseaseMajor Depressive DisorderSchizophrenia
Clobazam (Onfi)(Onfi)	Approved	GABA-A receptorSmall molecule	Epilepsy
Vigabatrin (Sabril)(Sabril)	Approved	GABA transaminase (GABA-T)Small molecule	Epilepsy
Vortioxetine(Trintellix)	Approved	Serotonin transporter + multiple 5-HT receptorsSmall molecule	Major Depressive Disorder
Bexicaserin	Phase 3	Serotonin 5-HT2C receptor (agonist)Small molecule	Epilepsy
Droxidopa (Northera)(Northera)	Phase 3	norepinephrine precursorSmall molecule	Parkinson's Disease
Lu AF28996	Phase 2	D1/D2Small molecule	Parkinson's Disease

Research

Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.

Research

Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.